ArticleSexually transmitted diseases2025
Assessing Attitudes and Knowledge of Mpox Vaccine Among Unvaccinated Men Who Have Sex With Men.
Article in Sexually transmitted diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors Associated with Mpox Vaccination Uptake Among Women of Transgender Experience and Transfeminine People in New York City, 2024.AIDS and behavior · 2026Article
- Mpox Vaccination and Willingness to Participate in Mpox Vaccine Research Among Sexual and Gender Minority Adults with and Without HIV in the United States.Prevention science : the official journal of the Society for Prevention Research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe 2022 mpox outbreak disproportionately affected gay, bisexual, and other men who have sex with men (GBMSM). Mpox cases continue to be reported nationally. Vaccination is a tool to prevent the spread of and serious disease from mpox. To understand mpox vaccine uptake and hesitancy, a virtual focus group with unvaccinated GBMSM was conducted.
methodsIn November 2022, a 60-minute, virtual focus group was conducted within an artificial intelligence (AI) platform that engages participants in chat-based conversation. The AI system uses machine learning and natural language processing to analyze and provide results immediately to the moderator. Descriptive frequencies, cross-tabulations, and qualitative themes were analyzed.
resultsFifty-one GBMSM aged 18 to 55 years participated, of whom 12 had attempted to get the mpox vaccine. The top barriers in accessing the vaccine included challenges in scheduling appointments (4 of 12), available vaccine locations (3 of 12), and transportation (2 of 12). Nine participants reported not wanting the vaccine, and 22 were undecided; of these, 15 (4 of 9 and 11 of 22, respectively) said they did not think they needed the vaccine due to low perceived risk or monogamy. Among the undecided, after receiving health messaging about mpox, 12 of 22 said the messaging made them reconsider getting the vaccine.
conclusionDuring an outbreak, many unvaccinated GBMSM who may be at increased risk for mpox either wanted the vaccine or, with appropriate health messaging, may be open to getting the vaccine. Messaging about mpox vaccine efficacy, potential side effects, and how to access the vaccine may improve vaccine uptake especially as cases continue to occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.